Sale!
Rated 5.00 out of 5 based on 4 customer ratings
(4 customer reviews)

IGF1 LR3 (1mg)

Original price was: $99.95.Current price is: $94.95.

Availability: 5 in stock

Research-Grade | 99%+ Purity | Third-Party Tested

IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a synthetic analog of endogenous insulin-like growth factor-1, engineered with two structural modifications that dramatically enhance its research utility over native IGF-1. The substitution of arginine for glutamic acid at position 3, combined with the addition of a 13-amino acid N-terminal extension peptide, produces a compound with significantly reduced affinity for IGF-binding proteins (IGFBPs) and a substantially extended plasma half-life transforming a rapidly cleared endogenous hormone into a stable, long-acting research tool.

IGF1 LR3 (1mg)

SKU igf1-lr3 Category

The biological significance of these modifications lies in IGF-1’s relationship with its binding proteins. In physiological conditions, the majority of circulating IGF-1 is bound to IGFBPs rendering it biologically inactive and limiting its receptor engagement. By dramatically reducing IGFBP affinity, IGF-1 LR3 maintains a far greater proportion of its active, unbound form in research systems, enabling more complete and sustained IGF-1 receptor engagement than equivalent concentrations of native IGF-1 would achieve. This translates directly into enhanced research signal clarity and more robust, reproducible experimental outcomes.

IGF-1 LR3 signals primarily through the IGF-1 receptor (IGF-1R) a receptor tyrosine kinase that activates the PI3K/Akt and MAPK/ERK signaling cascades governing cellular proliferation, differentiation, survival, and metabolic regulation. These pathways are among the most extensively studied in cell biology, oncology, and metabolic science positioning IGF-1 LR3 as a central research tool across multiple high-priority scientific disciplines.

Research applications include cellular proliferation and differentiation signaling studies, IGF-1 receptor binding kinetics and downstream pathway investigations, skeletal muscle protein synthesis and hypertrophy mechanism research, glucose metabolism and insulin signaling crosstalk studies, IGF-binding protein interaction and displacement research, cancer biology and tumor growth factor pathway investigations, and anti-aging and cellular senescence mechanism studies.

Every vial is independently third-party tested via HPLC and mass spectrometry, with complete COA documentation confirming structural accuracy and 99%+ purity. 

Molecular Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
Molecular Weight: 9,117.58 g/mol
Storage: Lyophilized at −20°C | Reconstitute under sterile conditions

FOR RESEARCH USE ONLY

IGF1 LR3 1mg

Two doses

4 reviews for IGF1 LR3 (1mg)

  1. Rated 5 out of 5

    Todd Davis

    If you are researching packing on lean muscle, try this!

  2. Rated 5 out of 5

    Admin

    The product arrived well presented with clear identification and research-only labeling. The specifications were easy to understand and review.

  3. Rated 5 out of 5

    Admin

    I appreciated the clean packaging and transparent product details. Everything from the concentration information to the research documentation was organized clearly.

  4. Rated 5 out of 5

    Admin

    A professionally presented research product with straightforward labeling. The available batch and testing information added useful transparency when reviewing the product.

Add a review

Your email address will not be published. Required fields are marked *

COAS

PRODUCT BATCH TESTING ORDERED SAMPLE RECEIVED STATUS ACTION
BPC157 10mg 021 1 JULY 2025 7 JULY 2025 CURRENT View COA
IGF-1 LR3 1mg 020 2 APRIL 2026 13 APRIL 2026 CURRENT View COA
PT-141 021 2 FEB 2026 13 FEB 2026 CURRENT View COA
Retatrutide 20mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
Semiglutide 10mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
Semiglutide 30mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
TB-500 021 2 FEB 2026 13 FEB 2026 CURRENT View COA
Tesamorelin 10mg 021 1 JULY 2025 7 JULY 2025 CURRENT View COA
Tirzepatide 30mg 020 2 MAY 2026 13 MAY 2026 CURRENT View COA
Scroll to Top